ClinicalTrials.gg
RecruitingNCT07860580Updated Oct 6, 2026

Alpha-Tectorin, Interleukin-10 and Thiol-Disulfide Homeostasis in Children With Congenital Hearing Loss

An observational study in Congenital Hearing Loss and Sensorineural Hearing Loss, sponsored by Harran University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged Up to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Harran University · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
120
Ages
Up to 17 Years
Sex
All
01

Study summary

Congenital hearing loss is one of the most common sensory disorders of childhood, and the structural, immunologic and oxidative mechanisms involved in its development are incompletely understood. This case-control study aims to evaluate serum alpha-tectorin and interleukin-10 (IL-10) levels and thiol-disulfide homeostasis in children with congenital sensorineural hearing loss (cochlear implant users and hearing aid users) compared with healthy children with normal hearing. The findings are expected to contribute to a better understanding of the mechanisms underlying congenital hearing loss and to the identification of potential diagnostic and prognostic biomarkers.

Read the detailed description

This cross-sectional case-control study is conducted at the Departments of Otorhinolaryngology and Audiology, Harran University Faculty of Medicine, Sanliurfa, Turkey. Pediatric patients with congenital sensorineural hearing loss confirmed by audiological testing (auditory brainstem response, otoacoustic emissions and/or pure-tone audiometry) are enrolled prospectively in three groups: (1) children who have undergone cochlear implantation for congenital hearing loss and actively use the implant (n=40); (2) children with congenital hearing loss who have not undergone cochlear implantation and actively use hearing aids (n=40); and (3) age- and sex-matched healthy children with normal audiological evaluation (n=40).

Written informed consent is obtained from the legal guardians of all participants, and assent is obtained from the children where appropriate. Age, sex, birth history, perinatal risk factors, comorbidities, medications, degree of hearing loss, device type and duration of device use are recorded using a standard data collection form.

Approximately 5 mL of venous blood is collected from each participant. Serum is separated by centrifugation and stored at -80 C until analysis. Serum alpha-tectorin and IL-10 levels are measured quantitatively with commercial enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturers' instructions. Thiol-disulfide homeostasis (native thiol, total thiol and disulfide levels and their ratios) is determined with an automated spectrophotometric method.

Biochemical parameters are compared between groups and analyzed in relation to clinical characteristics and the degree of hearing loss. Normality is assessed with the Kolmogorov-Smirnov and/or Shapiro-Wilk tests. Group comparisons are performed with the independent samples t-test or Mann-Whitney U test, and one-way ANOVA or Kruskal-Wallis test, as appropriate; categorical variables are compared with the chi-square or Fisher's exact test. Correlations are evaluated with Pearson or Spearman analysis, and multivariable linear regression is used to identify factors associated with biomarker levels. A p value \<0.05 is considered statistically significant.

02

Conditions studied

  • Congenital Hearing Loss
  • Sensorineural Hearing Loss

Keywords

  • Alpha-Tectorin
  • Interleukin-10
  • Thiol-Disulfide Homeostasis
  • Oxidative Stress
  • Cochlear Implant
  • Hearing Aid
  • Biomarker
03

In context

Hearing Loss, Sensorineural

348 studies on the registry are indexed under Hearing Loss, Sensorineural; 103 are open to participants now.

This study's planned enrollment of 120 is above the median of 70 across 86 observational studies indexed under Hearing Loss, Sensorineural.

Browse Hearing Loss, Sensorineural studies →

Lead sponsor

Harran University is the lead sponsor of 64 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Children under 18 years of age with congenital sensorineural hearing loss who use cochlear implants or hearing aids, and age- and sex-matched healthy children with normal hearing, evaluated at the Otorhinolaryngology and Audiology clinics of Harran University Faculty of Medicine Hospital, Sanliurfa, Turkey.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Congenital Hearing Loss Groups (Cochlear Implant Group and Hearing Aid Group)

  • Age under 18 years
  • Congenital sensorineural hearing loss diagnosed at the Otorhinolaryngology outpatient clinic and confirmed by audiological testing (auditory brainstem response, otoacoustic emissions and/or pure-tone audiometry)
  • Active use of a cochlear implant (Cochlear Implant Group) or active use of a hearing aid without cochlear implantation (Hearing Aid Group)
  • No condition preventing collection of a peripheral blood sample
  • Written from the parent or legal guardian

Healthy Control Group

  • Age under 18 years
  • No diagnosis of hearing loss and normal audiological evaluation
  • No condition preventing collection of a peripheral blood sample
  • Written informed consent from the parent or legal guardian

Exclusion criteria

Exclusion Criteria (all groups):

  • Syndromic hearing loss
  • Acute infection, chronic inflammatory disease, disease or other systemic disease
  • History of or active malignant disease
  • Immunodeficiency or use of therapy
  • Use of systemic , biologic agents or immunomodulatory therapy within the last 4 weeks
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
120 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Cochlear Implant Group

    Children under 18 years of age with audiologically confirmed congenital sensorineural hearing loss who have undergone cochlear implantation and actively use the implant (n=40).

    Other: Blood sample collection

  • Hearing Aid Group

    Children under 18 years of age with audiologically confirmed congenital sensorineural hearing loss who have not undergone cochlear implantation and actively use hearing aids (n=40).

    Other: Blood sample collection

  • Healthy Control Group

    Age- and sex-matched healthy children under 18 years of age with normal audiological evaluation and no history of hearing loss (n=40).

    Other: Blood sample collection

Interventions

  • OtherBlood sample collection

    Collection of approximately 5 mL of venous blood for measurement of serum alpha-tectorin, interleukin-10 and thiol-disulfide homeostasis parameters; no additional intervention is applied.

06

What researchers measure

Primary outcomes

  1. Serum alpha-tectorin level

    Serum alpha-tectorin concentration measured by ELISA, compared among the cochlear implant, hearing aid and healthy control groups.

    Time frame: At enrollment (single blood sample)

  2. Serum interleukin-10 (IL-10) level

    Serum IL-10 concentration measured by ELISA, compared among the cochlear implant, hearing aid and healthy control groups.

    Time frame: At enrollment (single blood sample)

  3. Serum thiol-disulfide homeostasis parameters

    Native thiol, total thiol and disulfide levels (umol/L) and disulfide/native thiol, disulfide/total thiol and native thiol/total thiol ratios measured by an automated spectrophotometric method, compared among the cochlear implant, hearing aid and healthy control groups.

    Time frame: At enrollment (single blood sample)

Secondary outcomes

  1. Correlation of biomarker levels with degree of hearing loss

    Correlation of serum alpha-tectorin, IL-10 and thiol-disulfide parameters with the degree of hearing loss (mild, moderate, severe, profound) determined by audiological evaluation, and with device type and duration of device use, in children with congenital hearing loss.

    Time frame: At enrollment (single blood sample)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared in order to protect participant confidentiality in accordance with national personal data protection regulations (KVKK).

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Feb 2027, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2026
First posted
Oct 6, 2026
StartActual
Apr 20, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Apr 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07860580
Lead sponsor
Harran University
Responsible party
Servet Erdemes (Assistant Professor of Otorhinolaryngology, Harran University) — Principal investigator
First posted
Oct 6, 2026
Start date
Apr 20, 2026
Primary completion
Feb 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Kemal Özgen, MD
Contact
kemal.ozgen47@harran.edu.tr
+905422272347
Servet Erdemes, MD
principal investigator · Harran University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion